Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Valenta Pharm JSC24 enrolled

Overview

Primary objective of the study: evaluation of the effect of food intake on the bioavailability of XC221 100 mg tablets after a single oral administration in fed or fasted condition. Additional objective of the study: evaluation of pharmacokinetic parameters, safety and tolerability of XC221 100 mg tablets in healthy volunteers after single oral administration in fed or fasted condition.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

XC221 100 mg tabletsDRUG

XC221, 3 discrete doses separated by 7-day wash-out periods

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy male and female volunteers aged 18 to 45 years (inclusive). 2. Presence of written consent of the volunteer to participate in the study in accordance with applicable law. 3. Body mass index (BMI) within the range of 18.5 ≤ BMI ≤ 30 kg/m2 with a body weight not less than 45 kg and not more than 100 kg. 4. Verified diagnosis "healthy": no deviations from the reference values of the data of standard clinical, laboratory and instrumental methods of examination. 5. The consent of the volunteer (including the partner) to use adequate methods of contraception during the study and 3 weeks after its completion. 6. Hemodynamic and other vital signs within normal limits (reference intervals are 60-90 bpm at rest for heart rate (HR), 16-20 breaths/min for respiratory rate (RR), 35.5 to 36.9°C for body temperature, normal blood pressure (BP) is considered to be systolic blood pressure (SBP) in the range of 110-130 mmHg; diastolic blood pressure (DBP) is 60-85 mmHg). Exclusion Criteria: 1. Hypersensitivity to the active substance XC221 (N-\[2-(1H-imidazol-4-yl)-ethyl\]-6-oxo-δ-lactam) and/or any other component of the drug product. 2. A history of allergy. 3. A history of bronchial asthma, recurrent nasal or paranasal sinus polyposis, allergic rhinitis. 4. Hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome. 5. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine, digestive, urinary, hematopoietic, immune and musculoskeletal systems, mental illness in the history. 6. Acute infectious diseases (including influenza, acute respiratory infections) within 30 days prior to the study. 7. Surgical interventions on the gastrointestinal tract in the anamnesis (except appendectomy). 8. Taking any medications, including vitamins, herbal preparations, and dietary supplements within 14 days prior to screening. 9. Taking medications that have significant effects on hemodynamics or liver function (barbiturates, omeprazole, cimetidine, etc.) for less than 30 days before screening. 10. Vital signs outside the reference intervals: SBP less than 110 mmHg or greater than 130 mmHg; DBP less than 60 mmHg or greater than 85 mmHg; HR less than 60 bpm or greater than 90 bpm; body temperature less than 35.5 or greater than 36.9° C, RR less than 16 or greater than 20 bpm. 11. Laboratory values outside the reference intervals. 12. Intake of more than 10 units of alcohol per week (where each unit equals 30 ml of spirits or 120 ml of wine or 330 ml of beer) or anamnestic evidence of alcoholism, drug addiction, substance abuse, drug abuse. 13. Smoking more than 10 cigarettes per day and failure to abstain from smoking 48 hours before the study and during the hospital stay. 14. Special diet (e.g., vegetarian, vegan, restricted salt intake) or lifestyle (night work, extreme physical activity). 15. Consumption of alcohol, caffeine, and xanthine-containing products 72 hours before taking the drug product. 16. Consumption of citrus fruits, cranberries and products containing them, preparations or products containing St. John's wort - 7 days before taking the IP. 17. 17. Dehydration due to diarrhea, vomiting, or other reason within the last 24 hours prior to IP administration. 18. Positive result of examination for antibodies to HIV type 1 and 2, syphilis, markers of hepatitis B and C. 19. Positive result of rapid test for COVID-19. 20. Positive breath alcohol test. 21. Positive urine drug test (cocaine, marijuana, amphetamine, methamphetamine, morphine, barbiturates). 22. Pregnancy, breastfeeding, positive urine pregnancy test (for women of preserved reproductive potential). 23. Use of hormonal contraceptives (oral, transdermal, injectable, implantable) by a female volunteer for 2 months prior to the drug administration. 24. Donation of blood (450 ml or more) within 30 days prior to the study. 25. Participation in a clinical drug study of any phase within 90 days prior to the start of the study. 26. Unavailability for observation during the study, inability to keep the visit schedule, inability to be hospitalized for the required duration, high likelihood of problems with successful insertion of a venous catheter or performing a forearm vein puncture. 27. Belonging to a vulnerable group of volunteers (minors; incapacitated; people with limited free will or possibly participating under compulsion (serving a sentence in prison, being in custody in detention centers, military personnel)), as well as law enforcement officers. 28. Other reasons that, in the opinion of the researcher, prevent the participation of the volunteer in the research or create an unreasonable risk. Withdrawal criteria: 1. Withdrawal of consent to participate in the study. 2. SAE, irrespective of causal relationship to drug intake. 3. Any other AE if the researcher believes it is in the best interest of the volunteer to discontinue participation in the study. 4. Missing two consecutive or four or more blood sampling points to determine pharmacokinetic parameters during the same period of the pharmacokinetics study. 5. Violation of study protocol requirements (including because the volunteer refuses to cooperate with the investigator, is late to the clinic, etc.). 6. Volunteer is undergoing or requires treatment that may affect the pharmacokinetic parameters of the drug. 7. Volunteer requires inpatient treatment while participating in the study. 8. Vomiting and/or diarrhea in volunteer within 24 hours prior to the drug administration or within 3 hours (2 maximum Tmax for XC221) after the drug administration. 9. Positive urine drug test result. 10. Positive breath alcohol test. 11. Positive urine pregnancy test. 12. Positive test for COVID-19. 13. Discontinuation of the study at the discretion of the Sponsor or regulatory agency.

Locations (1)

Limited Liability Company "Research Center Eco-Safety"

Saint Petersburg, Russia

Outcomes

Primary Outcomes

Pharmacokinetics - Cmax

Maximum plasma concentration (Cmax) of XC221GI (active ingridient) and XC221A (metabolite)

Time frame: From 0 to 12 hours after dosing on Day 1, Day 8, and Day 15

Pharmacokinetics - AUC0-t

Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of XC221GI (active ingridient) and XC221A (metabolite)

Time frame: From 0 to 12 hours after dosing on Day 1, Day 8, and Day 15

Pharmacokinetics - AUC0-inf

Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of XC221GI (active ingridient) and XC221A (metabolite)

Time frame: From 0 to 12 hours after dosing on Day 1, Day 8, and Day 15

Secondary Outcomes

Safety and Tolerability: adverse event (AE) number and frequency

Number and frequency of adverse events (AEs) or serious AEs (SAEs)

Time frame: From the screening (and signing informed consent form) to Day 16 of the study or to an early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: adverse event (AE) characteristics

Description and severity of AEs or serious AEs (SAEs), concomitant therapy for AEs/SAEs, causal relationship with XC221, outcomes.

Time frame: From the screening (and signing informed consent form) to Day 16 of the study or to an early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: vital signs - systolic blood pressure (SBP)

SBP, mmHg

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Safety and Tolerability: vital signs - diastolic blood pressure (DBP)

DBP, mmHg

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: vital signs - respiratory rate (RR)

RR, breaths per minute

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: vital signs - heart rate (HR)

HR, beats per minute

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: vital signs - body temperature

Body temperature, centigrade scale

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: physical examination results

Physical examination results

Time frame: Screening, from Day -1 to Day 2, from Day 7 to Day 9, from Day 14 to Day 16 and/or on early termination visit within the time frame of the study (from Day -1 to Day 16)

Safety and Tolerability: urinalysis - color

Color of the urine